Adenosine A3 receptor mod News

|||||||||| NTM-006 / Neumentum
Update on NTM-006, a Novel Orally-Active Non-Opioid Analgesic: Molecular-Modeling Consistent with Allosteric Modulation of the Adenosine A3 Receptor () - Sep 19, 2022 - Abstract #PAINWeek2022PAINWeek_219;
The results of the molecular modeling reported here supports this hypothesis. The combination of binding processes would be consistent with NTM-006's in vitro , animal model, and clinical characteristics of broad-spectrum and pronounced analgesic efficacy, and long-duration of analgesic action.

|||||||||| [VIRTUAL] PROTON PUMP INHIBITORS (PPI) INDUCES COLONIC TIGHT JUNCTION BARRIER (TJ) DYSFUNCTION VIA AN UPREGULATION OF TJ PORE FORMING CALUDIN-2 PROTEIN (Epithelial Cell Biology/Function in Inflammation) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_236;
Conclusion A3AR modulates intestinal inflammation in UC through GSDMD-mediated intestinal epithelial cell pyroptosis. We propose a novel mechanism by which A3AR-GSDMD interaction affects UC through pyroptosis, suggesting that A3AR is a potential target for the treatment of UC.

|||||||||| [VIRTUAL] ADENOSINE A3 RECEPTOR INTERACTS WITH GASDERMIN D TO MODULATE INTESTINAL EPITHELIAL CELL PYROPTOSIS IN ULCERATIVE COLITIS (POSTER OF DISTINCTION) (Epithelial Cell Biology/Function in Inflammation) - Feb 5, 2021 - Abstract #CCCongress2021CCCongress_228;
Conclusion A3AR modulates intestinal inflammation in UC through GSDMD-mediated intestinal epithelial cell pyroptosis. We propose a novel mechanism by which A3AR-GSDMD interaction affects UC through pyroptosis, suggesting that A3AR is a potential target for the treatment of UC.



	Diseases Companies Products Productz Mechanisms of Action Sites